Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures - Summary - MDSpire

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • By

  • Mohammed Nabil Quraishi

  • Jonathan Cheesbrough

  • Peter Rimmer

  • Benjamin H Mullish

  • Naveen Sharma

  • Elena Efstathiou

  • Animesh Acharjee

  • Georgios Gkoutus

  • Arzoo Patel

  • Julian R Marchesi

  • Stephane Camuzeaux

  • Katie Chappell

  • Maria A Valdivia-Garcia

  • James Ferguson

  • Matthew J Brookes

  • Martine Walmsley

  • Amanda E Rossiter

  • Willem van Schaik

  • Ross S McInnes

  • Rachel Cooney

  • Michael Trauner

  • Andrew D Beggs

  • Tariq H Iqbal

  • Palak J Trivedi

  • December 14, 2024

  • 0 min

Share

Objective:

To explore specific mucosal changes associated with clinical remission under oral vancomycin treatment in patients with primary sclerosing cholangitis-associated inflammatory bowel disease.

Key Findings:
  • Oral vancomycin induced clinical remission in 12 out of 15 patients.
  • Significant reductions in fecal calprotectin were observed.
  • Changes in gut microbiota included reduced Lachnospiraceae and increased Enterobacteriaceae, along with changes in Blautia and Bacteroides.
  • Downregulation of pathways related to SCFA metabolism and bile acid biotransformation was noted.
  • Colitis activity relapsed after withdrawal of vancomycin.
Interpretation:

Four weeks of oral vancomycin treatment can induce remission in PSC-IBD, but the effects are not sustained post-treatment, indicating a need for ongoing management strategies to maintain remission.

Limitations:
  • Small sample size limits generalizability and the ability to detect specific efficacy endpoints.
Conclusion:

Oral vancomycin shows potential for inducing remission in PSC-IBD, but further studies are needed to understand long-term effects and the underlying mechanisms.

Original Source(s)

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • by Mohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, Benjamin H Mullish, Naveen Sharma, Elena Efstathiou, Animesh Acharjee, Georgios Gkoutus, Arzoo Patel, Julian R Marchesi, Stephane Camuzeaux, Katie Chappell, Maria A Valdivia-Garcia, James Ferguson, Matthew J Brookes, Martine Walmsley, Amanda E Rossiter, Willem van Schaik, Ross S McInnes, Rachel Cooney, Michael Trauner, Andrew D Beggs, Tariq H Iqbal, Palak J Trivedi

  • December 14, 2024

Related Content

Trends in Research on Autoimmune Liver Disorders and Gut Microbiota (1989–2025): A Bibliometric and Visualization Study Utilizing the Web of Science Core Collection Database

Hidden Gut Factor in Liver Disease

Healthy microbiome linked to reduced liver injury from Vibrio infection

  • May 8, 2026

  • 3 min
Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists